IDEXX Laboratories sets the pace with raised 2026 guidance, analysts back the stock
25.06.2026 - 19:29:37 | ad-hoc-news.de
By Anna Wagner, Analysts & Consensus desk. Reviewed prior to publication on 2026-06-25, 19:29.
IDEXX Laboratories (US45168D1046) tightened its profile on the NASDAQ after raising its 2026 revenue and earnings guidance in early May. The veterinary diagnostics specialist now pairs that update with a clear Buy consensus from Wall Street analysts, according to fresh data from investing platforms.
What the guidance change shows
On 5 May 2026, IDEXX Laboratories reported first quarter revenue of about 1.14 billion US dollars, up roughly 14 percent year on year and ahead of prior consensus, and simultaneously lifted its full year outlook, as summarized in a detailed TIKR analysis of the Q1 figures. The company now guides 2026 revenue to a corridor of 4.675 billion to 4.760 billion dollars, versus earlier indications closer to the middle of the 4.5 billion dollar range.
At the same time, management lifted its 2026 earnings per share target, setting a new band of 14.45 to 14.90 dollars for the full year, compared with a prior outlook around 14 dollars per share, according to the same breakdown of the guidance update. Normalized EPS in the first quarter reached about 3.47 dollars, already tracking ahead of last year and giving a data point for that raised target corridor.
Consensus estimates and analyst stance
For the coming quarters, analysts expect IDEXX Laboratories to maintain robust earnings growth, with normalized EPS projections of around 3.94 dollars for the June 2026 quarter, 3.78 dollars for the third quarter and 3.45 dollars for the fourth, implying roughly 14 dollars EPS at the street midpoint for 2026, according to the same TIKR-based consensus overview. That trajectory broadly aligns with the company’s raised guidance range.
Across 14 analysts tracked by Investing.com, the IDEXX Laboratories stock carries a Buy rating on average, with 9 Buy recommendations, 5 Hold ratings and a single Sell, and an average 12 month price target around 709 US dollars per share. This implies a mid?20 percent upside versus recent trading levels and places IDEXX alongside other growth?oriented healthcare names within the NASDAQ?100.
All news and analysis on the IDEXX Laboratories shares
Charts, disclosures and further quarterly updates on IDEXX Laboratories are bundled in the dedicated topic section and on the company’s investor relations pages.
The product engine behind IDEXX
IDEXX Laboratories generates most of its revenue from veterinary diagnostics platforms such as the inVue Dx analyzer family and the Catalyst chemistry systems, which are placed in animal hospitals and clinics worldwide, supported by recurring consumables and software fees. Additional income streams come from reference laboratory services and livestock and poultry testing solutions.
Where the IDEXX shares trade now
The IDEXX Laboratories shares (US45168D1046) most recently closed on NASDAQ at 549.16 US dollars on 2026-06-24, with that level also cited by several market data providers as the latest official close.
Key data on the IDEXX Laboratories shares
- Company: IDEXX Laboratories, Inc.
- ISIN: US45168D1046
- WKN: 888210
- Ticker: IDXX
- Trading venue: NASDAQ
- Price (as of 2026-06-24, 16:00): 549.16 USD
- Market cap: 45.0 billion USD (as of late June 2026, rounded, based on the latest share price and reported share count)
- Sector / industry: Health Care - Diagnostics & Research
- Index membership: NASDAQ-100
- Next earnings date: 2026-08-01
This article is for informational purposes only and does not constitute investment advice or a recommendation to buy or sell securities. All data are based on publicly available sources considered reliable but are not guaranteed for accuracy or completeness.
